These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11717596)

  • 1. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.
    Bittl JA; Chaitman BR; Feit F; Kimball W; Topol EJ
    Am Heart J; 2001 Dec; 142(6):952-9. PubMed ID: 11717596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.
    Bittl JA; Strony J; Brinker JA; Ahmed WH; Meckel CR; Chaitman BR; Maraganore J; Deutsch E; Adelman B
    N Engl J Med; 1995 Sep; 333(12):764-9. PubMed ID: 7643883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators.
    Bittl JA; Feit F
    Am J Cardiol; 1998 Oct; 82(8B):43P-49P. PubMed ID: 9809891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
    N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty.
    Bittl JA; Ahmed WH
    Am J Cardiol; 1998 Oct; 82(8B):50P-56P. PubMed ID: 9809892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
    Carswell CI; Plosker GL
    Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions.
    Shah PB; Ahmed WH; Ganz P; Bittl JA
    J Am Coll Cardiol; 1997 Nov; 30(5):1264-9. PubMed ID: 9350925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
    Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients.
    Seybert AL
    Pharmacotherapy; 2002 Jun; 22(6 Pt 2):112S-118S. PubMed ID: 12064568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
    Antman EM; McCabe CH; Braunwald E
    Am Heart J; 2002 Feb; 143(2):229-34. PubMed ID: 11835024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalirudin for patients with acute coronary syndromes.
    Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
    N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
    Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
    Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
    Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
    Lincoff AM; Kleiman NS; Kottke-Marchant K; Maierson ES; Maresh K; Wolski KE; Topol EJ
    Am Heart J; 2002 May; 143(5):847-53. PubMed ID: 12040347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
    Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM;
    Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.